Author/Authors :
Ian McKeith، نويسنده , , Jacobo Mintzer، نويسنده , , Dag Aarsland، نويسنده , , David Burn، نويسنده , , Helen Chiu، نويسنده , , Jiska Cohen-Mansfield، نويسنده , , Dennis Dickson، نويسنده , , Bruno Dubois and members of the PréAL study، نويسنده , , John E Duda، نويسنده , , Howard Feldman، نويسنده , , Serge Gauthier، نويسنده , , Glenda Halliday، نويسنده , , Brian Lawlor، نويسنده , , Carol Lippa، نويسنده , , Oscar L. Lopez، نويسنده , , Jo?o Carlos Machado، نويسنده , , John OʹBrien، نويسنده , , Jeremy Playfer and Wayne Reid on behalf of the International Psychogeriatric Association Expert Meeting on DLB، نويسنده ,
Abstract :
Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinsonʹs disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.
